{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:25:01Z","timestamp":1778883901458,"version":"3.51.4"},"reference-count":20,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>The standard of care for patients with neuromyelitis optica (NMO) has become highly unequal globally. Sufficient data have been published to demonstrate that NMO is a disabling\u2014and at times, fatal\u2014disease needing preventive immunosuppressive treatment. Since 2019, there are multiple regulatory authority-approved disease-modifying therapies (DMTs) for aquaporin-4 antibody seropositive NMO for patients. Reframing the picture of NMO globally is now needed. When considered as a disease of high mortality when left untreated, parallel programs to those for cancer, HIV\/AIDS, or tuberculosis can be considered. Nine collective goals for rectifying global inequities in NMO diagnosis and treatment are proposed.<\/jats:p>","DOI":"10.1177\/13524585231179108","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T05:49:25Z","timestamp":1686376165000},"page":"932-935","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Rectifying global inequities in neuromyelitis optica diagnosis and treatment"],"prefix":"10.1177","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4293-8115","authenticated-orcid":false,"given":"Farrah J","family":"Mateen","sequence":"first","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA, USA\/Harvard Medical School, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Personal communications by e-mail, May 4 and 5, 2023","author":"Genentech, Alexion and Horizon Therapeutics","year":"2023","unstructured":"Genentech, Alexion and Horizon Therapeutics. Personal communications by e-mail, May 4 and 5, 2023. San Francisco, CA: Genentech, Boston, MA: Alexion, Dublin: Horizon Therapeutics, 2023."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02310-z"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.5.1107"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900866"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901747"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30078-8"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15355"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577790"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001089"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102542"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102353"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.4103\/0028-3886.355118"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.10.108"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-020-0557-x"},{"key":"e_1_3_2_17_2","unstructured":"Global rituximab biosimilars market report 2020-2030: COVID-19 impacts growth and change 2021 https:\/\/www.globenewswire.com\/en\/news-release\/2021\/01\/07\/2155050\/28124\/en\/Global-Rituximab-Biosimilars-Market-Report-2020-2030-COVID-19-Impacts-Growth-and-Change.html (accessed 12 March 2023)."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01028"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103716"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.2015.000570"},{"key":"e_1_3_2_21_2","unstructured":"Right to care: USAID commemorates 20 years of the President\u2019s emergency plan for AIDS relief https:\/\/www.usaid.gov\/global-health\/health-areas\/hiv-and-aids\/usaid-commememorates-pepfar-20th-anniversary\/RighttoCare (accessed 8 May 2023)."}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231179108","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13524585231179108","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13524585231179108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:12:08Z","timestamp":1777695128000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13524585231179108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1177\/13524585231179108"],"URL":"https:\/\/doi.org\/10.1177\/13524585231179108","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]}}}